Catalio Capital Management LP, a life sciences investment firm managing over $1 billion in assets with offices in New York, Baltimore and London, has closed its inaugural special situations fund, Catalio Credit Opportunities Fund I, with over $85 million in commitments from new and existing institutional investors.

Through this fund, Catalio works to provide biomedical technology companies with debt and equity services to fit their financing needs. It will target small- and mid-sized private companies at various stages of growth. The fund has made multiple investments in 2022 and looks to capitalize on debt and structured equity opportunities.

“In this challenging market, we are seeing significant demand from biotech companies for structured capital financing solutions to reach the next step in their evolution,” comments George Petrocheilos and Jacob Vogelstein, co-founders and managing partners of Catalio. “We believe that this strategy provides exciting biotech companies the necessary capital and flexibility to scale their platforms.”